BWA
TTNP

Beam Wealth Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Beam Wealth Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17
Closed -$2K – 174
2019
Q4 		$2K Buy
+17
New +$2.05K ﹤0.01% 149

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Beam Wealth Advisors's TTNP Position: Q1 2020 in Review

Beam Wealth Advisors sold out of Titan Pharmaceuticals (TTNP) in Q1 2020, closing a stake of 17 shares — an estimated $2K sold.

Beam Wealth Advisors first reported a position in TTNP in Q4 2019 and held it in 1 quarter. The position peaked at $2K in Q4 2019. 19 funds tracked by Wall St. Rank hold TTNP as of Q1 2020.

  • Beam Wealth Advisors reported no remaining Titan Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Beam Wealth Advisors sold 17 Titan Pharmaceuticals shares in Q1 2020, an estimated $2K.
  • Beam Wealth Advisors first reported a position in Titan Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Beam Wealth Advisors's Titan Pharmaceuticals position peaked at $2K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2020.

Based on Beam Wealth Advisors's 13F filing for Q1 2020, filed 8 Apr 2020.